# PrE1005 (NCT07285239)

> Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07285239
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: PrECOG, LLC.
- Conditions: Multiple Myeloma
- Interventions: Arm A: Belantamab Mafodotin; Arm B: Daratumumab Hyaluronidase; Bortezomib; Lenalidomide; Dexamethasone
- Enrollment: 500
- Primary outcome: MRD Negative Status
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- X threads: 15

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pre1005-nct07285239

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07285239", "email": "<work email>"}; the inbox owner confirms by the emailed link.